Metastatic Breast Cancer Clinical Trials

71 studies are recruiting for metastatic breast cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

   The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal g…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Baptist Health Herbert Wertheim Cancer Institute, Miami, Florida

   Locations

   3 in total

   Run by

   Reshma L. Mahtani, D.O.

   See if you can join NCT06263543 on ClinicalTrials.gov

2. Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

   This phase II trial evaluates the effect of capecitabine on tumor response using imaging and tumor markers to adjust dose (adaptive therapy) in patients with estrogen receptor (ER) positive, HER2 negative breast cancer that has spread from where it first started to other areas in the body (metastat…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mayo Clinic in Arizona, Scottsdale, Arizona

   Run by

   Mayo Clinic

   See if you can join NCT06525766 on ClinicalTrials.gov

3. Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

   The purpose of this research is to determine the expression of prostate specific membrane antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-negative, androgen receptor (AR)-positive metastatic breast cancer, and to determine its role in resistance to the anti-androgen, bicalutamide.…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT04573231 on ClinicalTrials.gov

4. Generative AI Patient Education Module for Breast Oncology

   This study evaluates the safety, accuracy, and impact of an artificial intelligence (AI) tool designed to support patient education in breast cancer care for breast oncology patients under selected physicians care within the University of California, San Francisco breast cancer center and affiliate…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   University of California, San Francisco

   See if you can join NCT07512271 on ClinicalTrials.gov

5. A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

   PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines o…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Alabama Oncology, Birmingham, Alabama

   Locations

   53 in total

   Run by

   Puma Biotechnology, Inc.

   See if you can join NCT06369285 on ClinicalTrials.gov

6. Fast-Her: Fasting Effects on Breast Cancer Treatment

   We hypothesize that promoting a fasting state will strengthen the anti-cancer effects of PI3K inhibitors in metastatic breast cancer (MBC) treatment. The primary objective of this study is to assess acceptability of prolonged fasting in this population.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Minnesota, Minneapolis, Minnesota

   Run by

   University of Minnesota

   See if you can join NCT07624617 on ClinicalTrials.gov

7. A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

   The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an effective treatment for people with oligometastatic breast cancer. Participants will stay on their usual drug therapy while they receive SBRT. …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   8 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05534438 on ClinicalTrials.gov

8. A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

   The purpose of this study is to test whether the combination of lenvatinib, pembrolizumab, and fulvestrant is a safe and effective treatment that causes few or mild side effects in people with ER+/HER2- metastatic breast cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06110793 on ClinicalTrials.gov

9. Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

   This study is a prospective evaluation of systemic, intravenous high-dose methotrexate (HD-MTX, 8 g/m2) in patients with triple negative, HER2-positive, and hormone refractory breast cancer with leptomeningeal metastasis (LMD) with or without brain parenchymal involvement.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

   Locations

   3 in total

   Run by

   Wake Forest University Health Sciences

   See if you can join NCT02422641 on ClinicalTrials.gov

10. Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

    The aim of this study is to identify the optimal dose for EP0062 as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    14 in total

    Run by

    Ellipses Pharma

    See if you can join NCT05573126 on ClinicalTrials.gov

11. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treat…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Mayo Clinic - Scottsdale, Scottsdale, Arizona

    Locations

    224 in total

    Run by

    LeonaBio

    See if you can join NCT05696626 on ClinicalTrials.gov

12. Scalp Cooling in MBC

    This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab govitecan, trastuzumab deruxtecan, or eribulin. The name of the study interve…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04986579 on ClinicalTrials.gov

13. CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

    This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil) are safe and effective at controlling the cancer in patients with metastatic triple Human Epiderm…

    Stage

    Phase 1

    Ages

    18 to 99

    Site

    University of Chicago Comprehensive Cancer Center, Chicago, Illinois

    Locations

    7 in total

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT05029999 on ClinicalTrials.gov

14. ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

    The goal of this study is to evaluate the safety and efficacy of elacestrant in combination with trastuzumab deruxtecan (T-DXd) in participants with hormone receptor-positive (HR+), HER2-low or HER2-ultralow, metastatic breast cancer that is resistant to prior CDK4/6 inhibitor and endocrine therapy…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Run by

    Kristina A. Fanucci

    See if you can join NCT07198724 on ClinicalTrials.gov

15. Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

    This is a research study to test the safety and effectiveness of using the drug alpelisib together with chemotherapy (nab-paclitaxel) and a drug called L-NMMA in patients with HER2 negative metastatic or locally advanced metaplastic breast cancer, who have not responded to previous treatments. Part…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    National Institute of Health Clinical Center, Bethesda, Maryland

    Locations

    3 in total

    Run by

    The Methodist Hospital Research Institute

    See if you can join NCT05660083 on ClinicalTrials.gov

16. DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

    This study is being done to determine if there is a pattern associated with response to endocrine therapy alone and in combination with CDK4/6 inhibitor used for hormone receptor positive HER2 negative breast cancer.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mayo Clinic in Florida, Jacksonville, Florida

    Run by

    Mayo Clinic

    See if you can join NCT06388122 on ClinicalTrials.gov

17. A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

    The purpose of this study is to test different doses of abemaciclib to find the best dose in participants while receiving hormone therapy and radiation therapy.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering at Basking Ridge (All protocol activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06678269 on ClinicalTrials.gov

18. Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns

    The purpose of this observational study is to learn about the HER2 heterogeneity and its impact on benefit from trastuzumab deruxtecan in metastatic breast cancer. The main question it aims to answer is: - Does the heterogeneity of HER2 expression level and spatial distribution in different tissues…

    Stage

    Not phased

    Ages

    18 to 80

    Site

    Yale Cancer Center, New Haven, Connecticut

    Locations

    26 in total

    Run by

    Sun Yat-sen University

    See if you can join NCT06551220 on ClinicalTrials.gov

19. Promoting Resilience in Women With Breast Cancer (PRISM -MBC)

    This pilot interventional study evaluates the change from baseline to post-intervention in resilience and other patient-reported outcomes for individuals with a recent diagnosis of metastatic breast cancer (MBC) participating in the Promoting Resilience in Women with Breast Cancer (PRISM) intervent…

    Stage

    Not phased

    Ages

    18 and older

    Site

    The University of Alabama, Birmingham, Alabama

    Locations

    2 in total

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06855654 on ClinicalTrials.gov

20. A Study of Surgery and Radiotherapy in People With Breast Cancer

    The researchers are doing this study to see if the combination of surgery, locoregional radiation therapy, SBRT (stereotactic body radiation therapy), and the usual approach is more effective in treating oligometastatic HER2-positive breast cancer than the usual approach alone. The researchers will…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07053085 on ClinicalTrials.gov

21. STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)

    Determine whether subjects harboring ESR1-mutant/amplified breast cancer have a higher rate of clinical benefit from 17b-estradiol therapy than subjects with ESR1-wild-type breast cancer

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

    Run by

    Dartmouth-Hitchcock Medical Center

    See if you can join NCT05716516 on ClinicalTrials.gov

22. Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

    This is a Phase 1b/2, open-label, parallel-arms pilot study in men and post-menopausal women with hormone receptor positive (HR+), HER2- advanced or metastatic breast cancer with an alteration in the PI3K pathway, including a mutation of the PIK3CA gene, PTEN loss, or AKT1 mutation, designed to det…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Loma Linda University Cancer Center, Loma Linda, California

    Locations

    10 in total

    Run by

    SynDevRx, Inc.

    See if you can join NCT05455619 on ClinicalTrials.gov

23. Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

    Patients with metastatic breast cancer with at least 2 brain metastases will receive pembrolizumab every 3 weeks. Patients will undergo stereotactic radiosurgery (SRS) to one of the brain lesions. Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg…

    Stage

    Phase 1

    Ages

    19 to 90

    Site

    Weill Cornell Medicine, New York, New York

    Locations

    3 in total

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT03449238 on ClinicalTrials.gov

24. Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

    This is a phase 2, open-label, singled-arm clinical trial determining efficacy of combination therapy with anastrozole, fulvestrant and abemaciclib in subjects with breast cancer. These are subjects who are newly diagnosed advanced or metastatic hormone receptor positive breast cancer or subjects w…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

    Run by

    University of California, Irvine

    See if you can join NCT05524584 on ClinicalTrials.gov

25. Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

    This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Hartford Healthcare, Hartford, Connecticut

    Locations

    12 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT03808337 on ClinicalTrials.gov